Discover open access scientific publications

Search, annotate, share and cite publications

Publications by O.A. O'Connor

Targeting the Peripheral T-Cell Lymphoma (Ptcl) Epigenome With Oral 5-Azacytidine and Romidepsin: Results and Clinical-Molecular Correlations From a Phase 2 Study

Hematological Oncology

English

Oral Azacytidine (Aza) and Romidepsin (R) Reveals Promising Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)

Hematological Oncology

English

A Phase 1 Study of Pralatrexate Plus Romidepsin Reveals Marked Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)

Hematological Oncology

English

Response to A+chp by Cd30 Expression in the Echelon-2 Trial

Hematological Oncology

English

Umbralisib and Carfilzomib Potently Inhibit Cap Dependent Translation in Lymphoma

Hematological Oncology

English

A First-In-Human Trial of the Novel Multi-Action Therapy Tinostamustine (Edo-S101) in Patients With Relapsed/Refractory (R/R) Hodgkin Lymphoma (Hl)

Hematological Oncology

English

Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients With Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Registration Directed Phase 2 Study

Hematological Oncology

English

Survival Benefit With Novel Agents in Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas (Ptcl): The Columbia University Experience

Hematological Oncology

English

Case Match Control Analysis of Propel Reveals a Survival Advantage for Patients With Relapsed PTCL Receiving Pralatrexate: A Novel Approach to Benchmark Drugs in Rare Diseases

Hematological Oncology

English

Analysis of Efficacy and Safety of Loncastuximab Tesirine (Adct-402) by Demographic and Clinical Characteristics in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by O.A. O'Connor

Targeting the Peripheral T-Cell Lymphoma (Ptcl) Epigenome With Oral 5-Azacytidine and Romidepsin: Results and Clinical-Molecular Correlations From a Phase 2 Study

Oral Azacytidine (Aza) and Romidepsin (R) Reveals Promising Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)

A Phase 1 Study of Pralatrexate Plus Romidepsin Reveals Marked Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)

Response to A+chp by Cd30 Expression in the Echelon-2 Trial

Umbralisib and Carfilzomib Potently Inhibit Cap Dependent Translation in Lymphoma

A First-In-Human Trial of the Novel Multi-Action Therapy Tinostamustine (Edo-S101) in Patients With Relapsed/Refractory (R/R) Hodgkin Lymphoma (Hl)

Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients With Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Registration Directed Phase 2 Study

Survival Benefit With Novel Agents in Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas (Ptcl): The Columbia University Experience

Case Match Control Analysis of Propel Reveals a Survival Advantage for Patients With Relapsed PTCL Receiving Pralatrexate: A Novel Approach to Benchmark Drugs in Rare Diseases

Analysis of Efficacy and Safety of Loncastuximab Tesirine (Adct-402) by Demographic and Clinical Characteristics in Relapsed/Refractory Diffuse Large B-Cell Lymphoma